Bain Capital Public Equity Management II’s Cytokinetics CYTK Stock Holding History

Bain Capital Public Equity Management II’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-340,926	Closed	-$13.4M	–	42
2022 Q2	$13.4M	Sell	340,926 -70,929	-17%	-$2.86M	0.66%	30
2022 Q1	$15.2M	Buy	411,855 +70,583	+21%	+$2.51M	0.49%	35
2021 Q4	$15.6M	Sell	341,272 -310,341	-48%	-$12M	0.52%	35
2021 Q3	$23.3M	Buy	651,613 +384,347	+144%	+$11.3M	0.81%	32
2021 Q2	$5.29M	Buy	267,266 +185,900	+228%	+$4.36M	0.23%	34
2021 Q1	$1.89M	Buy	+81,366	New	+$1.74M	0.08%	53

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bain Capital Public Equity Management II's CYTK Position: Q3 2022 in Review

Bain Capital Public Equity Management II sold out of Cytokinetics (CYTK) in Q3 2022, closing a stake of 340,926 shares — an estimated $13.4M sold.

Bain Capital Public Equity Management II first reported a position in CYTK in Q1 2021 and held it in 6 quarters. The position peaked at $23.3M in Q3 2021. 277 funds tracked by Wall St. Rank hold CYTK as of Q3 2022.

Bain Capital Public Equity Management II reported no remaining Cytokinetics position as of Q3 2022 after selling out during the quarter.
Bain Capital Public Equity Management II sold 340,926 Cytokinetics shares in Q3 2022, an estimated $13.4M.
Bain Capital Public Equity Management II first reported a position in Cytokinetics in Q1 2021 and held it in 6 quarters.
Bain Capital Public Equity Management II's Cytokinetics position peaked at $23.3M in Q3 2021.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2022.

Based on Bain Capital Public Equity Management II's 13F filing for Q3 2022, filed 14 Nov 2022.